- Article
Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey
- Richard O’Dwyer,
- Sophia Junker,
- Robert Szulkin,
- Scarlette Kienzle,
- Mairead Kearney and
- Srikala S. Sridhar
Background: For many decades, gemcitabine + cisplatin has been a preferred and accepted treatment option for patients with urothelial cancer (UC). In patients ineligible for standard-dose cisplatin, split-dose cisplatin is a promising alternative. Th...

